By: IPP Bureau
Last updated : January 14, 2026 4:01 pm
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Ameera Shah-led Metropolis Healthcare Limited, India’s second-largest and the most trusted pathology laboratory chain, announced the launch of its Centre of Genomics, marking a significant step in scaling its longstanding capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research.
The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties.
Metropolis has upgraded its genomics research with Illumina's NovaSeq X Series, boosting its capabilities with powerful, fast, and accurate DNA sequencing, capable of producing over 20,000 genomes yearly thanks to its advanced XLEAP-SBS chemistry, unlocking new genetic discoveries for better patient care.
Supporting the new NovaSeq X Series, Metropolis Healthcare's Centre of Genomics leverages existing multi-platform NGS infrastructure across its hubs, uniting molecular pathologists, scientists, bioinformaticians, and genetic counselors to deliver clinically meaningful insights from complex genomic data, driving precision medicine.
Commenting on the launch, Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said: “Genomics marks a decisive inflection point for diagnostics in India, expanding the role of laboratories from disease detection to risk prediction, therapy personalisation, and long-term disease management. As genomics increasingly informs lifelong medical decisions, leadership in this space is defined not by adoption alone, but by rigorous validation, deep expertise, quality assurance, and clinical responsibility. Through the Centre of Genomics, we bring together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations. Supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms.”
Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, said: “The Centre of Genomics has been designed to translate advanced genomic science into actionable clinical decision-making across high-impact disease areas, including oncology, reproductive health, neurology, transplant immunology, and rare diseases. Our differentiation lies in rigorous validation, multi-platform testing, and deep clinical integration, ensuring results are reliable and clinically meaningful. With over 220 validated genomic tests and a clear roadmap to expand beyond 500 assays over the next two to three years, the Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways.”
“As Illumina expands its presence in India, our mission is to make advanced sequencing technologies more accessible across the country,” said Suchita Dayanand, Country Head – India (Commercial), Illumina. “The NovaSeq X Series demonstrates our leadership in next-generation sequencing, and we are proud to see Metropolis Healthcare leveraging our most sustainable high-throughput sequencer to drive transformative research and innovation.”